Fisher Funds Management LTD Sells 242,305 Shares of Edwards Lifesciences Corporation $EW

Fisher Funds Management LTD reduced its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 31.8% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 519,594 shares of the medical research company’s stock after selling 242,305 shares during the quarter. Edwards Lifesciences accounts for about 1.2% of Fisher Funds Management LTD’s investment portfolio, making the stock its 25th largest holding. Fisher Funds Management LTD’s holdings in Edwards Lifesciences were worth $41,609,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. J. Derek Lewis & Associates Inc. purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth $323,000. Rockefeller Capital Management L.P. grew its position in shares of Edwards Lifesciences by 2.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 36,707 shares of the medical research company’s stock valued at $3,129,000 after purchasing an additional 922 shares in the last quarter. World Investment Advisors grew its position in shares of Edwards Lifesciences by 10.7% in the fourth quarter. World Investment Advisors now owns 39,986 shares of the medical research company’s stock valued at $3,409,000 after purchasing an additional 3,877 shares in the last quarter. Corient Private Wealth LLC raised its stake in shares of Edwards Lifesciences by 20.7% during the 4th quarter. Corient Private Wealth LLC now owns 100,051 shares of the medical research company’s stock valued at $8,547,000 after purchasing an additional 17,144 shares during the period. Finally, Hsbc Holdings PLC raised its stake in shares of Edwards Lifesciences by 0.7% during the 4th quarter. Hsbc Holdings PLC now owns 2,148,974 shares of the medical research company’s stock valued at $183,188,000 after purchasing an additional 15,577 shares during the period. 79.46% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on EW. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective for the company in a research report on Wednesday, April 1st. Mizuho set a $95.00 target price on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a report on Monday, April 13th. Robert W. Baird increased their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Truist Financial set a $90.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a report on Tuesday, June 16th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $95.96.

Edwards Lifesciences Stock Up 0.2%

Shares of NYSE EW opened at $87.51 on Monday. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average of $83.39 and a 200-day moving average of $83.13. The firm has a market capitalization of $50.39 billion, a price-to-earnings ratio of 46.55, a PEG ratio of 2.19 and a beta of 0.87. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $89.60.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same period last year, the firm posted $0.64 earnings per share. Edwards Lifesciences’s quarterly revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Sell-side analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president directly owned 98,611 shares in the company, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 81,038 shares of company stock valued at $6,683,255. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.